Blog

Dec 19, 2024, 08:08

T790M resistance mutations in EGFR+ lung cancer – EGFR Positive Lung Cancer UK

EGFR Positive Lung Cancer UK shared on X:

“New research offers hope for those with T790M resistance mutations in EGFR+ lung cancer. Scientists have identified CDDO-Me, a compound that shows potential in preclinical studies to stop tumour growth.”

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth

Authors: Rui Zhou, Ziqian Liu, Tongtong Wu, Xianwei Pan, Tongtong Li, Kaiting Miao, Yuru Li, Xiaohui Hu, Haigang Wu, Andrew M. Hemmings, Beier Jiang, Zhenzhen Zhang, Ning Liu

T790M resistance mutations in EGFR+ lung cancer - EGFR Positive Lung Cancer UK

Andrew M. Hemmings Beier Jiang cancer EGFR Positive Lung Cancer UK Haigang Wu Kaiting Miao Ning Liu OncoDaily Oncology Rui Zhou Tongtong Li Tongtong Wu Xianwei Pan Xiaohui Hu Yuru Li Zhenzhen Zhang Ziqian Liu

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers